Intriguingly, we found enhanced IRS2 mRNA expression in liver tissues from anti-TNFR1-treated compared to control-Ab-treated NAFLD mice (data not shown). This evidence concerns the gene TNFRSF1A and metabolic dysfunction-associated steatotic liver disease.